May 22, 2018 / 10:24 AM / in a month

BRIEF-Sublimity Therapeutics - Completed $64 Mln Financing To Further Development Of New Oral Ulcerative Colitis Drug Candidate

* SUBLIMITY THERAPEUTICS - COMPLETED $64 MILLION FINANCING TO FURTHER DEVELOPMENT OF STI-0529 FOR TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS

* SUBLIMITY THERAPEUTICS SAYS FINANCING WAS CO-LED BY ORBIMED AND LONGITUDE CAPITAL WITH PARTICIPATION FROM HBM HEALTHCARE INVESTMENTS. Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below